EGFR突变种类与临床疗效关联  

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Clinical Evaluation

作　　者：陈亚楠[1] 张菊[2] 刘文超[1] 

机构地区：[1]第四军医大学西京医院肿瘤科,陕西西安710032 [2]第四军医大学药学系基因所,陕西西安710032

出　　处：《现代生物医学进展》2011年第5期943-945,共3页Progress in Modern Biomedicine

基　　金：国家自然科学基金(30973437)

摘　　要：癌组织中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是应用靶向药物EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)治疗的一个重要相关因素及预测指标。对其突变的检测可以指导TKI类药物(TKIs)的最佳应用。该种突变常出现在非小细胞肺癌(NSCLC)中,尤其是在亚洲女性、肺腺癌、非吸烟者中,与非小细胞肺癌患者对TKIs治疗的敏感性密切相关。本文旨在探讨利用EGFR基因的已知突变热点的相关知识选择适合不同分子遗传学背景的群体或/和个体的"个体化"治疗方案,最终达到延长肺癌患者生存时间和提高生活质量的双重目的。Mutations in the epidermal growth factor receptor（EGFR） gene have been reported to be present in cancer organizes and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors,which suggest its usefulness as a biomarker.Morever,EGFR gene mutation was frequently tested in NSCLC,especially in Asians,females,nonsmokers,and adenocarcinomas.EGFR gene mutation was related to gefitinib therapy sensibility.This article was to discuss ＂individuation＂.Extension patient＇s life and enhancement quality of life could be achieved finally.

关 键 词：表皮生长因子受体(EGFR) 突变 非小细胞肺癌(NSCLC) 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]